The American Heart Association (AHA) and Germany-based Bayer have announced a collaboration to complete research on cerebral small vessel disease, chronic kidney disease and heart failure.
The AHA’s Institute for Precision Cardiovascular Medicine is now accepting applications for three grants, funded by Bayer. Each recipient will receive $150,000, according to a statement from AHA, and the program begins in July.
“Research in each of these areas is critical to provide individuals with better prevention and treatment options,” said Jennifer Hall, PhD, chief of the AHA Institute for Precision Cardiovascular Medicine, in a statement. “Through this collaboration with Bayer, the American Heart Association is able to support vital research to develop a deeper understanding of these diseases.”
The institute will use patient data to find personalized approaches to prevent and treat conditions like heart disease and stroke.
The deadline to apply is April 13. Awardees will be notified in June.
Senior Writer
As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.